Innate Pharma SA
IPHYF$211M
Micro CapNASDAQBiotechnology🇺🇸North America174 employees
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IPHYF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
MIS416
Secondary Progressive Multiple Sclerosis
IPH4102
Lymphoma, T-Cell
IPH6501
Non Hodgkin Lymphoma
IPH2101
Smoldering Multiple Myeloma
Monalizumab
Head and Neck Neoplasms
IPH2102 at 0.1 mg/kg
Acute Myeloid Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MIS416 | Phase 2 | Secondary Progressive Multiple Sclerosis | - | - |
IPH4102 | Phase 2 | Lymphoma, T-Cell | - | - |
IPH6501 | Phase 2 | Non Hodgkin Lymphoma | - | - |
IPH2101 | Phase 2 | Smoldering Multiple Myeloma | - | - |
Monalizumab | Phase 2 | Head and Neck Neoplasms | - | - |
IPH2102 at 0.1 mg/kg | Phase 2 | Acute Myeloid Leukemia | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply